[go: up one dir, main page]

GB2394223B - Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation - Google Patents

Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Info

Publication number
GB2394223B
GB2394223B GB0224306A GB0224306A GB2394223B GB 2394223 B GB2394223 B GB 2394223B GB 0224306 A GB0224306 A GB 0224306A GB 0224306 A GB0224306 A GB 0224306A GB 2394223 B GB2394223 B GB 2394223B
Authority
GB
United Kingdom
Prior art keywords
hydroxylase
dopamine
peripherally
beta
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB0224306A
Other versions
GB0224306D0 (en
GB2394223A (en
Inventor
David Alexander Learmonth
Patricio Manuel Vieira A Silva
Alexander Beliaev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of GB0224306D0 publication Critical patent/GB0224306D0/en
Priority to US10/681,578 priority Critical patent/US7125904B2/en
Priority to EP07076125A priority patent/EP1908760B1/en
Priority to AT07076124T priority patent/ATE500247T1/en
Priority to ARP030103711A priority patent/AR041589A1/en
Priority to DK07076125.9T priority patent/DK1908760T3/en
Priority to RU2005114021/04A priority patent/RU2332416C2/en
Priority to SI200331309T priority patent/SI1408038T1/en
Priority to DE60322642T priority patent/DE60322642D1/en
Priority to DK03256420T priority patent/DK1408038T3/en
Priority to BRPI0315143A priority patent/BRPI0315143B8/en
Priority to KR1020057006221A priority patent/KR101155159B1/en
Priority to EP07076122A priority patent/EP1914233B8/en
Priority to AT07076125T priority patent/ATE505465T1/en
Priority to KR1020127005102A priority patent/KR101350741B1/en
Priority to AT07076122T priority patent/ATE500248T1/en
Priority to EP03256420A priority patent/EP1408038B1/en
Priority to MXPA05003847A priority patent/MXPA05003847A/en
Priority to PT103029A priority patent/PT103029B/en
Priority to EP07076123A priority patent/EP1908759B1/en
Priority to DE60336772T priority patent/DE60336772D1/en
Priority to DE60336275T priority patent/DE60336275D1/en
Priority to EP07076124A priority patent/EP1911757B8/en
Priority to PL376224A priority patent/PL218537B1/en
Priority to ES03256420T priority patent/ES2309279T3/en
Priority to CA2501819A priority patent/CA2501819C/en
Priority to PCT/GB2003/004430 priority patent/WO2004033447A1/en
Priority to SI200331986T priority patent/SI1908760T1/en
Priority to DE60336276T priority patent/DE60336276D1/en
Priority to JP2004542666A priority patent/JP4620464B2/en
Priority to ES07076123T priority patent/ES2384118T3/en
Priority to AT03256420T priority patent/ATE403652T1/en
Priority to AT07076123T priority patent/ATE550335T1/en
Priority to AU2003271945A priority patent/AU2003271945B2/en
Publication of GB2394223A publication Critical patent/GB2394223A/en
Priority to US11/533,462 priority patent/US7259271B2/en
Priority to GB0702981A priority patent/GB2432158B/en
Priority to GB0702982A priority patent/GB2432159B/en
Application granted granted Critical
Publication of GB2394223B publication Critical patent/GB2394223B/en
Priority to HK08111214.9A priority patent/HK1116188B/en
Priority to CY20081101204T priority patent/CY1108452T1/en
Priority to CY20111100639T priority patent/CY1112457T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0224306A 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation Expired - Lifetime GB2394223B (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
US10/681,578 US7125904B2 (en) 2002-10-11 2003-10-08 Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
DE60336275T DE60336275D1 (en) 2002-10-11 2003-10-10 Process for the preparation of 3- (1,3-dihydroimidazole-2-thion-1-yl) -chromans and thiochromans as dopamine-beta-hydroxylase inhibitor
EP07076124A EP1911757B8 (en) 2002-10-11 2003-10-10 Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
ARP030103711A AR041589A1 (en) 2002-10-11 2003-10-10 PERIPHERALLY SELECTIVE DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND METHOD FOR PREPARATION
DK07076125.9T DK1908760T3 (en) 2002-10-11 2003-10-10 Chromatic and thiochroman-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine beta-hydroxylase and methods for their preparation
RU2005114021/04A RU2332416C2 (en) 2002-10-11 2003-10-10 Imidazole derivatives, method of their production, pharmaceutical composition on their basis, their use as peripherically selective inhibitors dophamine-beta-hydrolaze and intermediate compounds
SI200331309T SI1408038T1 (en) 2002-10-11 2003-10-10 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
DE60322642T DE60322642D1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripheral-selective inhibitors of dopamine beta-hydroxylases
DK03256420T DK1408038T3 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally selective inhibitors dopamine beta-hydroxylase
BRPI0315143A BRPI0315143B8 (en) 2002-10-11 2003-10-10 compound, pharmaceutical composition, and use of a compound
KR1020057006221A KR101155159B1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
EP07076122A EP1914233B8 (en) 2002-10-11 2003-10-10 Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors
AT07076125T ATE505465T1 (en) 2002-10-11 2003-10-10 CHROMAN- AND THIOCHROMAN-3-YL-1,3-DIHYDROIMIDAZOLE AS INHIBITORS OF DOPAMINE BETA-HYDROXYLASE AND METHOD FOR THE PRODUCTION THEREOF
KR1020127005102A KR101350741B1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
AT07076122T ATE500248T1 (en) 2002-10-11 2003-10-10 SILYL-PROTECTED HYDROXYMETHYL-CARBAMOYLALKYL KETONES AS INTERMEDIATE IN THE PRODUCTION OF DOPAMINE BETA-HYDROXYLASE INHIBITORS
EP03256420A EP1408038B1 (en) 2002-10-11 2003-10-10 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
MXPA05003847A MXPA05003847A (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase.
PT103029A PT103029B (en) 2002-10-11 2003-10-10 DOPAMINE-BETA-HYDROXYLASE INHIBITORS SELECTIVELY PERIPHERED AND METHOD FOR THEIR PREPARATION
ES03256420T ES2309279T3 (en) 2002-10-11 2003-10-10 DERIVATIVES OF IMIDAZOL AND ITS USE AS PERIFERICALLY SELECTIVE INHIBITORS OF BETA-HYDROXYLASE DOPAMINE.
DE60336772T DE60336772D1 (en) 2002-10-11 2003-10-10 Chroman and thiochroman-3-yl-1,3-dihydroimidazoles as dopamine beta-hydroxylase inhibitors and methods for their preparation
EP07076125A EP1908760B1 (en) 2002-10-11 2003-10-10 Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation
PL376224A PL218537B1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
EP07076123A EP1908759B1 (en) 2002-10-11 2003-10-10 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation
AT07076124T ATE500247T1 (en) 2002-10-11 2003-10-10 METHOD FOR PRODUCING 3-(1,3-DIHYDROIMIDAZOLE-2-THION-1-YL)-CHROMANES AND THIOCHROMANES AS A DOPAMINE BETA-HYDROXYLASE INHIBITOR
CA2501819A CA2501819C (en) 2002-10-11 2003-10-10 Imidazole derivative and their use as peripherally-selective inhibitors of dopa nine-beta-hydroxylase
PCT/GB2003/004430 WO2004033447A1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
SI200331986T SI1908760T1 (en) 2002-10-11 2003-10-10 Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation
DE60336276T DE60336276D1 (en) 2002-10-11 2003-10-10 Silyl-protected hydroxymethyl-carbamoylalkyl ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors
JP2004542666A JP4620464B2 (en) 2002-10-11 2003-10-10 Imidazole derivatives as peripherally selective inhibitors of dopamine-beta-hydroxylase and their use
ES07076123T ES2384118T3 (en) 2002-10-11 2003-10-10 3,4-Dihydro-3-amino-2H-1-benzopyran and -benzothiopyran derivatives as dopamine-beta-hydroxylase inhibitors and methods for their preparation
AT03256420T ATE403652T1 (en) 2002-10-11 2003-10-10 IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERAL-SELECTIVE INHIBITORS OF DOPAMINE BETA-HYDROXYLASES
AT07076123T ATE550335T1 (en) 2002-10-11 2003-10-10 3,4-DIHYDRO-3-AMINO-2H-1-BENZOPYRAN AND - BENZOTHIOPYRAN DERIVATIVES AS DOPAMINE BETA-HYDROXYLASE INHIBITORS AND METHOD FOR THE PRODUCTION THEREOF
AU2003271945A AU2003271945B2 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
US11/533,462 US7259271B2 (en) 2002-10-11 2006-09-20 Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0702981A GB2432158B (en) 2002-10-11 2007-02-15 Intermediates for manufacturing peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
GB0702982A GB2432159B (en) 2002-10-11 2007-02-15 Intermediates for manufacturing peripherally-selective inhibitors of dopamine-beta-hydroxylase
HK08111214.9A HK1116188B (en) 2002-10-11 2008-10-09 Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation
CY20081101204T CY1108452T1 (en) 2002-10-11 2008-10-24 IMIDAZOLI PRODUCTS AND USE THESE AS PERIODICALLY EXTRACTIVE INHIBITORS OF DOPOPAMIN-β-HYDROXYLUM
CY20111100639T CY1112457T1 (en) 2002-10-11 2011-07-01 CHROMO- AND THIROXROMANO-3-YlO-1,3-dihydro-imidazole as inhibitors of dopamine-B-hydroxylation, and their production methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase

Publications (3)

Publication Number Publication Date
GB0224306D0 GB0224306D0 (en) 2002-11-27
GB2394223A GB2394223A (en) 2004-04-21
GB2394223B true GB2394223B (en) 2007-05-16

Family

ID=9945777

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0223719A Withdrawn GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A Expired - Lifetime GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB0223719A Withdrawn GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase

Country Status (10)

Country Link
KR (1) KR101350741B1 (en)
CN (1) CN100393715C (en)
AR (2) AR041589A1 (en)
AT (5) ATE550335T1 (en)
CY (2) CY1108452T1 (en)
DE (4) DE60336772D1 (en)
DK (2) DK1408038T3 (en)
ES (5) ES2309279T3 (en)
GB (2) GB2393958A (en)
SI (2) SI1908760T1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
CA2822681C (en) * 2010-12-22 2020-07-14 Bial-Portela & Ca., S.A. Crystalline forms of 1-[(3r)-6,8-difluoro-3,4-dihydro-2h-1-benzopyran-3-yl]-1,3-dihydro-5- [2-[(phenylmethyl)amino]ethyl] -2h-imidazole-2-thione and processes for their preparations
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029165A2 (en) * 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029165A2 (en) * 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors

Also Published As

Publication number Publication date
GB2393958A (en) 2004-04-14
SI1908760T1 (en) 2011-05-31
ATE403652T1 (en) 2008-08-15
ES2364919T3 (en) 2011-09-16
DE60322642D1 (en) 2008-09-18
AR095674A2 (en) 2015-11-04
CN100393715C (en) 2008-06-11
CY1112457T1 (en) 2015-12-09
ATE500247T1 (en) 2011-03-15
GB0224306D0 (en) 2002-11-27
ATE500248T1 (en) 2011-03-15
DE60336772D1 (en) 2011-05-26
GB0223719D0 (en) 2002-11-20
ES2361938T3 (en) 2011-06-24
KR101350741B1 (en) 2014-01-10
KR20120038014A (en) 2012-04-20
DE60336275D1 (en) 2011-04-14
ES2361939T3 (en) 2011-06-24
GB2394223A (en) 2004-04-21
HK1116188A1 (en) 2008-12-19
AR041589A1 (en) 2005-05-26
ES2309279T3 (en) 2008-12-16
ATE550335T1 (en) 2012-04-15
DK1908760T3 (en) 2011-07-25
CY1108452T1 (en) 2014-04-09
ES2384118T3 (en) 2012-06-29
ATE505465T1 (en) 2011-04-15
DE60336276D1 (en) 2011-04-14
SI1408038T1 (en) 2008-10-31
DK1408038T3 (en) 2008-11-24
CN1726211A (en) 2006-01-25

Similar Documents

Publication Publication Date Title
GB2432158B (en) Intermediates for manufacturing peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1648316A4 (en) Vertebral retainer-distracter and method of using same
AU2003220586A1 (en) Game piece and system and method of use
PL375052A1 (en) Pharmaceutical pig and method of use
AU2003231048A8 (en) Transposon system and methods of use
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
IL164703A0 (en) ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
IL196847A0 (en) P38 inhibitors and method of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
GB0325192D0 (en) Method of use
AU2003282558A1 (en) Nanopellets and method of making nanopellets
AU2003295410A8 (en) Piston and method of manufacture
IL169648A0 (en) Novel structures and method of preparation
AU2003299441A8 (en) Nf-hev compositions and methods of use
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
EP1509111A4 (en) Anaerobic tea steeper and method of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
EP1615942A4 (en) Polymerase inhibitor and method of using same
GB0308934D0 (en) Labels and method of manufacture thereof
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
AU2002246950A1 (en) Hydrocapsules and method of preparation
AU2003294684A8 (en) Ketoprofen compositions and methods of making them
AU2003287802A1 (en) Palpometer and methods of use thereof

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20221017